Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
71%(5 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
2
25%
Ph phase_3
1
13%

Phase Distribution

5

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (62.5%)
Phase 22 (25.0%)
Phase 31 (12.5%)

Trials by Status

terminated113%
completed788%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_1

Study Evaluating Betrixaban in Pediatric Participants

NCT03346083
completedphase_1

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

NCT00999336
completedphase_1

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

NCT02596100
completedphase_1

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

NCT01765868
completedphase_2

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

NCT00375609
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03346083Phase 1

Study Evaluating Betrixaban in Pediatric Participants

Terminated
NCT00999336Phase 1

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Completed
NCT02596100Phase 1

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Completed
NCT01765868Phase 1

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

Completed
NCT00375609Phase 2

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Completed
NCT01583218Phase 3

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Completed
NCT00742859Phase 2

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

Completed
NCT03397888Phase 1

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8